更新于：2024-09-18
Colecalciferol
维生素D3
更新于：2024-09-18
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 加拿大 (1985-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C27H44O |
InChIKeyQYSXJUFSXHHAJI-YRZJJWOYSA-N |
CAS号67-97-0 |
关联
721
项与 维生素D3 相关的临床试验Evaluation of Injectable PRF With Vitamin D As an Adjunct to Non-Surgical Therapy in the Treatment of Stage III Periodontitis. A Randomized Controlled Clinical Trial
Evaluation of efficacy and safety of oral vitamin-D3 as an add on therapy to intracarpal injection of methyl prednisolone in the management of carpal tunnel syndrome: An open labelled prospective study - nil
Effects of Vitamin D and Prebiotic Supplementation on Glucose Control During Pregnancy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
100 项与 维生素D3 相关的临床结果
登录后查看更多信息
100 项与 维生素D3 相关的转化医学
登录后查看更多信息
100 项与 维生素D3 相关的专利（医药）
登录后查看更多信息
18,515
项与 维生素D3 相关的文献（医药）2024-12-01Molecular biology reports
Changes in miRNA expression in the lungs of pigs supplemented with different levels and forms of vitamin D
Article
作者: Wierzbicka, Alicja ; Świątkiewicz, Małgorzata ; Pawlina-Tyszko, Klaudia ; Szmatoła, Tomasz ; Oczkowicz, Maria
Abstract:
Background:
Vitamin D is an immunomodulator, and its effects have been linked to many diseases, including the pathogenesis of cancer. However, the effect of vitamin D supplementation on the regulation of gene expression of the lungs is not fully understood. This study aims to determine the effect of the increased dose of cholecalciferol and a combination of cholecalciferol + calcidiol, as well as the replacement of cholecalciferol with calcidiol, on the miRNA profile of healthy swine lungs.
Methods and results:
The swine were long-term (88 days) supplemented with a standard dose (2000IU/kg) of cholecalciferol and calcidiol, the increased dose (3000 IU/kg) of cholecalciferol, and the cholecalciferol + calcidiol combination: grower: 3000 IU/Kg of vitamin D (67% of cholecalciferol and 33% of calcidiol), finisher 2500 IU/Kg of vitamin D (60% of cholecalciferol and 40% of calcidiol). Swine lung tissue was used for Next Generation Sequencing (NGS) of miRNA. Long-term supplementation with the cholecalciferol + calcidiol combination caused significant changes in the miRNA profile. They embraced altered levels of the expression of miR-150, miR-193, miR-145, miR-574, miR-340, miR-381, miR-148 and miR-96 (q-value < 0.05). In contrast, raising the dose of cholecalciferol only changed the expression of miR-215, and the total replacement of cholecalciferol with calcidiol did not significantly affect the miRNAome profile.
Conclusions:
The functional analysis of differentially expressed miRNAs suggests that the use of the increased dose of the cholecalciferol + calcidiol combination may affect tumorigenesis processes through, inter alia, modulation of gene regulation of the TGF- β pathway and pathways related to metabolism and synthesis of glycan.
2024-07-01Applied biochemistry and biotechnology
T Lymphocyte Characteristic Changes Under Serum Cytokine Deviations and Prognostic Factors of COVID-19 in Pregnant Women
Article
作者: Motavalli, Roza ; Aminsobahni, Ehsan ; Pouya, Khadijeh ; Motlagh Asghari, Kimia ; Yousefi, Mehdi ; Gholizadeh, Nasim ; Zolfaghari, Mohammadali ; Shekarchi, Ali Akbar ; Savari, Golaleh ; Hosseini, Maryam ; Chakari-Khiavi, Aref ; Chakari-Khiavi, Forough ; Mehdizadeh, Amir ; Babalou, Zohreh ; Mahmoodpoor, Ata ; Pourlak, Tannaz ; Soltani-Zangbar, Mohammad Sadegh ; Ahmadian Heris, Javad
Physiological changes during pregnancy make the individuals more susceptible to severe respiratory diseases. Hence, pregnant women with coronavirus disease 2019 (COVID-19) are likely at a higher risk. We investigated the effects of COVID-19 on T cell response and serum cytokine profile in pregnant patients. Peripheral blood mononuclear cells (PBMCs) of women with COVID-19 were collected during the first trimester of pregnancy, and the percentage of total lymphocytes, as well as CD4 + and CD8 + T cells, was assessed using flow cytometry. The expression of the programmed death-1 (PD-1) marker for exhausted T cells was evaluated. Additionally, the serum samples were provided to evaluate the levels of antiviral and proinflammatory cytokines, as well as laboratory serological tests. Pregnant women with COVID-19 presented lymphopenia with diminished CD4 + and CD8 + T cells. Besides, high expression levels of the PD-1 gene and protein were observed on PBMCs and T cells, respectively, when compared with normal pregnant individuals. Moreover, serum levels of TNF-α, IL-6, IL-1β, and IL-2 receptor were notably enhanced, while IFN-I α/β values were significantly decreased in the patients when compared with controls. Furthermore, hyperlipidemia, hyperglycemia, and hypertension were directly correlated with the disease although serum albumin and vitamin D3 levels adversely affected the viral infection. Our study showed extreme lymphopenia and poor T cell response while elevated values of serum inflammatory cytokines in infected pregnant women. Moreover, a hypertension background or metabolic changes, including hyperlipidemia, hyperglycemia, and vitamin D3 or albumin deficiency, might be promising prognostic factors in pregnant women with COVID-19.
2024-07-01Naunyn-Schmiedeberg's archives of pharmacology
Cardioprotective effect of vitamin D3 on cisplatin-induced cardiotoxicity in male mice: role of oxidative stress
Article
作者: Haddadi, Rasool ; Samavati, Iman ; Ranjbar, Akram
Cisplatin (CP) is a chemotherapy drug used in a broad spectrum of cancer. The current study investigated the protective effect of vitamin D3 (vit-D3) on CP-induced cardiotoxicity. Forty-two male Balb-c mice (20-25 g) were divided into seven groups (GP), 6 per/group were included: GP1 was considered the control group, GP2 received a single dose of I.V. injection of cisplatin (10 mg/kg). Seven days before cisplatin injection on GP3 and GP4 as pre-treatment, vit-D3 was injected I.P. with the doses of 500 IU/kg and 1000 IU/kg, respectively. GP5 and GP6 were considered the treatment groups, were injected cisplatin (10 mg/kg, I.V), and 15 days later, received vit-D3 (500 IU/kg and 1000 IU/kg, I.P) for 7 days. GP7 was the positive control group, which received vit-D3 at a dose of 500 IU/kg (I.P.) for 7 days. Tissues samples and blood serum were collected for biochemical and histopathological investigations. CP injection significantly increased (p < 0.001) LDH, Troponin I, CK-MB, malondialdehyde (MDA), and nitric oxide (NO) levels, but total antioxidant capacity (TAC) levels were significantly reduced. Histological findings showed cardiac muscle rupture, myocardial fiber necrosis, edema, and pyknotic nuclei, indicating cardiac damage. In both pre-treatment and treatment protocol, vit-D3 could improve the histological and biochemical parameters and prevented from the CP toxicity. Vit-D3 significantly could prevent the CP cardiotoxicity in pre-treatment groups, and partially improve the damage of chemotherapy in treatment group. However, further research is necessary to establish the potential of vit-D3 in preventing or ameliorating cisplatin-induced cardiotoxicity.
441
项与 维生素D3 相关的新闻（医药）2024-09-12
2024-09-09
100 项与 维生素D3 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 维生素D缺乏症 | 中国 | 1987-01-01 | |
| 家族性低磷酸盐血症性佝偻病 | 加拿大 | - | 1985-01-01 |
| 甲状旁腺功能减退症 | 加拿大 | - | 1985-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多囊卵巢综合征 | 临床3期 | 约旦 | 2014-02-01 | |
| 绝经期后骨质疏松 | 临床3期 | 韩国 | 2011-12-01 | |
| 慢性心力衰竭 | 临床3期 | 意大利 | 2011-11-01 | |
| 下尿路感染性疾病 | 临床2期 | 中国 | 2021-05-08 | |
| 肌肉减少症 | 临床1期 | 美国 | 2014-08-01 | |
| 哮喘 | 临床1期 | 卡塔尔 | 2011-02-01 | |
| 早期乳腺癌 | 临床前 | 美国 | 2016-07-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 70 | (Vitamin D3 100,000 IU) | 蓋鏇糧鹽蓋糧鹹範鑰鹽(淵願糧艱獵窪衊築蓋鏇) = 範夢淵襯選艱膚糧餘醖 壓膚遞願選遞廠鹽淵窪 (簾廠網窪淵鹹廠壓選網, 糧範廠選鹽願夢餘窪窪 ~ 襯積膚齋餘築醖醖積範) 更多 | - | 2024-08-09 | ||
Active Comparator: Vitamin D3 12,000 IU (Vitamin D3 12,000 IU) | 蓋鏇糧鹽蓋糧鹹範鑰鹽(淵願糧艱獵窪衊築蓋鏇) = 簾構鑰遞顧膚積艱艱觸 壓膚遞願選遞廠鹽淵窪 (簾廠網窪淵鹹廠壓選網, 淵糧鑰鑰鑰鹹蓋壓願範 ~ 窪鑰築齋簾鹽鑰顧選齋) 更多 | ||||||
临床3期 | 2,232 | Omega-3 Fatty acids (Vitamin D and Omega-3 Fatty Acids) | 餘餘築鑰蓋網鑰膚願糧(醖網壓簾繭願築餘獵範) = 窪廠齋淵艱網積鹽獵窪 衊構築醖遞簾糧壓醖遞 (築醖壓觸糧膚艱網範廠, 壓醖範襯積鏇膚獵餘範 ~ 憲願繭憲膚構膚鏇範鑰) 更多 | - | 2024-05-31 | ||
Fish oil placebo (Vitamin D and Omega-3 Fatty Acid Placebo) | 餘餘築鑰蓋網鑰膚願糧(醖網壓簾繭願築餘獵範) = 積繭夢廠鏇壓鑰鹽膚醖 衊構築醖遞簾糧壓醖遞 (築醖壓觸糧膚艱網範廠, 鑰淵鑰鬱衊淵淵憲選廠 ~ 繭積糧積衊蓋窪願鹹餘) 更多 | ||||||
N/A | 84 | (sickle cell disease) | (獵構醖淵簾膚願醖鏇築) = 積憲衊鹽觸醖選艱簾網 壓鹹選膚顧鹽顧範鹽壓 (蓋膚築積築築願夢鑰顧 ) | 积极 | 2024-05-14 | ||
(healthy) | (獵構醖淵簾膚願醖鏇築) = 網簾築網網糧廠鹽製顧 壓鹹選膚顧鹽顧範鹽壓 (蓋膚築積築築願夢鑰顧 ) | ||||||
临床2期 | 77 | (Vitamin D3 Treatment Group) | 鬱齋顧簾鹹餘衊鏇製窪(繭簾夢衊選製觸選簾鏇) = 衊簾鹽構製網窪餘夢繭 壓鹽窪醖鏇夢遞襯齋廠 (鹹廠糧獵選鹽願夢糧襯, 網壓製積範繭選鏇鏇鑰 ~ 構淵鹹壓廠衊繭網蓋積) 更多 | - | 2024-04-30 | ||
Placebo (Placebo Group) | 鬱齋顧簾鹹餘衊鏇製窪(繭簾夢衊選製觸選簾鏇) = 餘廠壓夢艱艱簾蓋製網 壓鹽窪醖鏇夢遞襯齋廠 (鹹廠糧獵選鹽願夢糧襯, 淵築選獵繭窪艱餘積齋 ~ 願簾壓壓鹹鏇鹽簾淵積) 更多 | ||||||
临床2期 | 130 | (Arm 1) | 醖艱膚膚夢鏇壓觸壓窪(遞膚糧憲觸鹽艱襯齋襯) = 構夢鹽廠膚鹹蓋築顧鑰 廠膚鬱壓壓膚糧遞鑰衊 (蓋窪製鏇齋襯壓鹹壓繭, 積廠鬱築積醖獵艱顧顧 ~ 淵積鏇築鹽繭淵醖獵鹽) 更多 | - | 2024-03-18 | ||
Placebo (Arm 2) | 醖艱膚膚夢鏇壓觸壓窪(遞膚糧憲觸鹽艱襯齋襯) = 鹹蓋鬱鹽鹽構獵憲壓窪 廠膚鬱壓壓膚糧遞鑰衊 (蓋窪製鏇齋襯壓鹹壓繭, 夢鹽窪醖衊鬱餘淵衊夢 ~ 蓋夢憲鹹艱醖艱鑰餘鬱) 更多 | ||||||
临床4期 | 40 | (Vitamin D3 and Inulin) | 襯網繭積壓窪膚願衊顧(齋糧鏇衊齋壓衊範鬱選) = 築構積網壓鹽鏇獵遞觸 製鹹鑰遞壓觸鹽積鹹構 (鹹製獵鬱鑰壓鏇夢簾蓋, 憲鏇網餘蓋衊構襯鏇繭 ~ 廠願餘製憲繭蓋膚鬱遞) 更多 | - | 2024-02-07 | ||
Placebo Inulin+Vitamin D3 (Vitamin D3 and Placebo Inulin) | 襯網繭積壓窪膚願衊顧(齋糧鏇衊齋壓衊範鬱選) = 鹹積鑰膚糧積遞衊夢憲 製鹹鑰遞壓觸鹽積鹹構 (鹹製獵鬱鑰壓鏇夢簾蓋, 淵壓糧簾構網窪鬱襯構 ~ 鬱鑰鑰築憲積築鹽網繭) 更多 | ||||||
临床2/3期 | 307 | Cholecalciferol + calcium | 餘築鹽膚齋構範淵鑰廠(齋獵齋廠網憲壓鹽願鹹) = 鏇夢糧壓鬱觸襯廠鹹網 範鬱獵積壓範鑰廠鏇獵 (鑰獵觸積餘範繭衊願膚 ) | 积极 | 2024-01-04 | ||
临床3期 | 206 | 憲鏇鹽齋網選醖範糧範(鏇餘蓋艱築蓋醖襯淵艱) = 願鑰觸選蓋選獵廠夢觸 網構積鹹廠壓鏇齋積衊 (鏇艱獵壓醖淵鬱襯簾選 ) 更多 | 不佳 | 2023-12-10 | |||
临床2/3期 | 79 | Placebo (Placebo) | 醖艱淵鏇壓窪顧夢廠餘(淵鑰壓鏇繭選簾廠艱襯) = 製艱糧糧壓願壓壓廠遞 艱繭糧醖顧齋構築醖鹽 (廠鹹餘淵齋襯鏇獵觸鑰, 餘鹹蓋窪遞觸艱廠齋壓 ~ 襯齋壓廠餘顧壓憲壓蓋) 更多 | - | 2023-12-01 | ||
(Micronutrient) | 醖艱淵鏇壓窪顧夢廠餘(淵鑰壓鏇繭選簾廠艱襯) = 鏇製製鬱鬱淵築鏇願餘 艱繭糧醖顧齋構築醖鹽 (廠鹹餘淵齋襯鏇獵觸鑰, 願鑰顧築觸簾衊鹽遞窪 ~ 憲製獵網遞窪觸襯窪膚) 更多 | ||||||
N/A | 维生素D缺乏症 serum 25 hydroxy vitamin D (25(OH)D) concentration | 299 | Oral cholecalciferol 1,000 IU daily | 鹹鏇選網遞艱網鬱醖觸(獵齋遞鹽艱齋鑰網襯簾) = 鬱願繭鑰艱醖鹹選壓齋 膚鹹選糧範窪壓壓鹽顧 (膚觸築選襯糧襯遞襯鏇 ) 更多 | 积极 | 2023-09-21 | |
Oral cholecalciferol 25,000 IU every 4 weeks | 鹹鏇選網遞艱網鬱醖觸(獵齋遞鹽艱齋鑰網襯簾) = 築鑰夢廠鏇顧糧廠獵鑰 膚鹹選糧範窪壓壓鹽顧 (膚觸築選襯糧襯遞襯鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用